Dendritic cells

Contemporary Targeted Therapies in Rheumatology

Volumn , Issue , 2007, Pages 63-78

  Lutzky, Viviana ^a   Thomas, Ranjeny ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 40549115920     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (155)

1. Fazekas de St Groth B. The evolution of self-tolerance: A new cell arises to meet the challenge of self-reactivity. Immunol Today 1998; 19: 448-54.
2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392(6673): 245-52.
3. Inaba K, Steinman RM, Van Voorhis WC, Muramatsu S. Dendritic cells are critical accessory cells for thymus-dependent antibody responses in mouse and in man. Proc Natl Acad Sci U S A 1983; 80(19): 6041-5.
4. Kitamura H, Iwakabe K, Yahata T et al. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 1999; 89(7): 1121-8.
5. Schuler G, Steinman RM. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 1997; 186(8): 1183-7.
6. Brocker T. Survival of mature CD4 T lymphocytes is dependent on major histocompatibility complex class II-expressing dendritic cells. J Exp Med 1997; 186(8): 1223-32.
7. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-96.
8. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997; 9(1): 10-16.
9. Cella M, Scheidegger D, Palmer-Lehmann K et al.Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184(2): 747-52.
10. Sallusto F, Lanzavecchia A. Mobilizing dendritic cells for tolerance, priming, and chronic inflammation. J Exp Med 1999; 189(4): 611-14.
11. Sparwasser T, Koch ES, Vabulas RM et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 1998; 28(6): 2045-54.
12. Cella M, Salio M, Sakakibara Y et al. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med 1999; 189(5): 821-9.
13. De Smedt T, Pajak B, Muraille E et al. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med 1996; 184(4): 1413-24.
14. De Smedt T, Van Mechelen M, De Becker G et al. Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol 1997; 27(5): 1229-35.
15. Geissmann F, Revy P, Regnault A et al. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol 1999; 162(8): 4567-75.
16. de Jong EC, Vieira PL, Kalinski P, Kapsenberg ML. Corticosteroids inhibit the production of inflammatory mediators in immature monocyte-derived DC and induce the development of tolerogenic DC3. J Leukoc Biol 1999; 66(2): 201-4.
17. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193(2): 233-8.
18. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192(9): 1213-22.
19. Lutz MB, Kukutsch NA, Menges M, Rossner S, Schuler G. Culture of bone marrow cells in GM-CSF plus high doses of lipopolysaccharide generates exclusively immature dendritic cells which induce alloantigen-specific CD4 T cell anergy in vitro. Eur J Immunol 2000; 30(4): 1048-52.
20. Mehling A, Grabbe S, Voskort M et al. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol 2000; 165(5): 2374-81.
21. Lutz MB, Suri RM, Niimi M et al. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol 2000; 30(7): 1813-22.
22. Griffin MD, Lutz W, Phan VA et al. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U S A 2001; 98(12): 6800-5.
23. Hackstein H, Morelli AE, Larregina AT et al. Aspirin inhibits in vitro maturation and in vivo immunostimu-latory function of murine myeloid dendritic cells. J Immunol 2001; 166(12): 7053-62.
24. Lee JI, Ganster RW, Geller DA et al. Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: Association with reduced nuclear translocation of nuclear factor kappa B. Transplantation 1999; 68(9): 1255-63.
25. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997; 159(10): 4772-80.
26. Yoshimura S, Bondeson J, Foxwell BM, Brennan FM, Feldmann M. Effective antigen presentation by dendritic cells is NF-kappaB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines. Int Immunol 2001; 13(5): 675-83.
27. Giannoukakis N, Bonham CA, Qian S et al. Prolongation of cardiac allograft survival using dendritic cells treated with NF-kB decoy oligodeoxyribonucleotides. Mol Ther 2000; 1(5 Pt 1): 430-7.
28. Griffin MD, Lutz W, Phan VA et al. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U S A 2001; 98(12): 6800-5.
29. Rea D, van Kooten C, van Meijgaarden KE et al.Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. Blood 2000; 95(10): 3162-7.
30. Adorini L, Penna G, Giarratana N, Uskokovic M. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. J Cell Biochem 2003; 88(2): 227-33.
31. Burkly L, Hession C, Ogata L et al. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature 1995; 373(6514): 531-6.
32. Weih F, Carrasco D, Durham SK et al. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell 1995; 80(2): 331-40.
33. Wu L, D'Amico A, Winkel KD et al. RelB is essential for the development of myeloid-related CD8alpha-dendritic cells but not of lymphoid-related CD8alpha+ dendritic cells. Immunity 1998; 9(6): 839-47.
34. O'Sullivan BJ, MacDonald KP, Pettit AR, Thomas R. RelB nuclear translocation regulates B cell MHC molecule, CD40 expression, and antigen-presenting cell function. Proc Natl Acad Sci U S A 2000; 97(21): 11421-6.
35. O'Sullivan BJ, Thomas R. CD40 Ligation conditions dendritic cell antigen-presenting function through sustained activation of NF-kappaB. J Immunol 2002; 168(11): 5491-8.
36. Martin E, O'Sullivan B, Low P, Thomas R. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity 2003; 18(1): 155-67.
37. Nishizuka Y, Sakakura T. Thymus and reproduction: sex-linked dysgenesia of the gonad after neonatal thymectomy in mice. Science 1969; 166(906): 753-5.
38. Kojima A, Tanaka-Kojima Y, Sakakura T, Nishizuka Y. Prevention of postthymectomy autoimmune thyroiditis in mice. Lab Invest 1976; 34(6): 601-5.
39. Sakaguchi S, Sakaguchi N, Shimizu J et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182: 18-32.
40. Itoh M, Takahashi T, Sakaguchi N et al. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 1999; 162(9): 5317-26.
41. Sakaguchi S, Sakaguchi N, Shimizu J et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182: 18-32.
42. McHugh RS, Shevach EM, Thornton AM. Control of organ-specific autoimmunity by immunoregulatory CD4(+)CD25(+) T cells. Microbes Infect 2001; 3(11): 919-27.
43. Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 2000; 164(1): 183-90.
44. Zheng Z, Narita M, Takahashi M et al. Induction of T cell anergy by the treatment with IL-10-treated dendritic cells. Comp Immunol Microbiol Infect Dis 2004; 27(2): 93-103.
45. Yamazaki S, Iyoda T, Tarbell K, Olson K et al. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003; 198(2): 235-47.
46. Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 2004; 199(11): 1467-77.
47. Tang Q, Henriksen KJ, Bi M et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004; 199(11): 1455-65.
48. Groux H, O'Garra A, Bigler M et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389(6652): 737-42.
49. Weiner HL. Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes Infect 2001; 3(11): 947-54.
50. O'Garra A, Arai N. The molecular basis of T helper 1 and T helper 2 cell differentiation. Trends Cell Biol2000; 10(12): 542-50.
51. Lenschow DJ, Herold KC, Rhee L et al. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 1996; 5(3): 285-93.
52. Xu H, Heeger PS, Fairchild RL. Distinct roles for B7-1 and B7-2 determinants during priming of effector CD8+ Tc1 and regulatory CD4+ Th2 cells for contact hypersensitivity. J Immunol 1997; 159(9): 4217-26.
53. Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML. T-cell priming by type-1 and type-2 polarized dendritic cells: The concept of a third signal. Immunol Today1999; 20(12): 561-7.
54. Rabinovich GA, Daly G, Dreja H et al. Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J Exp Med 1999; 190(3): 385-98.
55. Gorczynski L, Chen Z, Hu J et al. Evidence that an OX-2-positive cell can inhibit the stimulation of type 1 cytokine production by bone marrow-derived B7-1 (and B7-2)-positive dendritic cells. J Immunol 1999; 162(2): 774-81.
56. Chang CC, Ciubotariu R, Manavalan JS et al.Tolerization of dendritic cells by T(S) cells: The crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 2002; 3(3): 237-43.
57. Becker JC, Vetter CS, Schrama D, Brocker EB, thor Straten P. Differential expression of CD28 and CD94/NKG2 on T cells with identical TCR beta variable regions in primary melanoma and sentinel lymph node. Eur J Immunol 2000; 30(12): 3699-706.
58. Speiser DE, Valmori D, Rimoldi D et al. CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. Eur J Immunol 1999; 29(6): 1990-9.
59. Vallejo AN, Brandes JC, Weyand CM, Goronzy JJ. Modulation of CD28 expression: distinct regulatory pathways during activation and replicative senescence. J Immunol 1999; 162(11): 6572-9.
60. Yen JH, Moore BE, Nakajima T et al. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med 2001; 193(10): 1159-67.
61. Kawano T, Cui J, Koezuka Y et al. CDld-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997; 278(5343): 1626-9.
62. Naumov YN, Bahjat KS, Gausling R et al. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc Natl Acad Sci U S A 2001; 98(24): 13838-43.
63. Fujihashi K, Taguchi T, Aicher WK et al. Immuno-regulatory functions for murine intraepithelial lymphocytes: gamma/delta T cell receptor-positive (TCR+) T cells abrogate oral tolerance, while alpha/beta TCR+ T cells provide B cell help. J Exp Med 1992; 175(3): 695-707.
64. Drakesmith H, Chain B, Beverley P. How can dendritic cells cause autoimmune disease? Immunol Today 2000; 21(5): 214-7.
65. Ludewig B, Zinkernagel RM, Hengartner H. Transgenic animal models for virus-induced autoimmune diseases. Exp Physiol 2000; 85(6): 653-9.
66. Morel PA, Vasquez AC, Feili-Hariri M. Immunobiology of DC in NOD mice. J Leukoc Biol 1999; 66(2): 276-80.
67. Ludewig B, Odermatt B, Ochsenbein AF, Zinkernagel RM, Hengartner H. Role of dendritic cells in the induction and maintenance of autoimmune diseases. Immunol Rev 1999; 169: 45-54.
68. Rosmalen JG, Homo-Delarche F, Durant S et al. Islet abnormalities associated with an early influx of dendritic cells and macrophages in NOD and NODscid mice. Lab Invest 2000; 80(5): 769-77.
69. Mannering SI, Harrison LC, Williamson NA et al. The insulin A-chain epitope recognized by human T cells is posttranslationally modified. J Exp Med 2005; 202(9): 1191-7.
70. Meyer O, Nicaise-Roland P, Santos MD et al.Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis. Arthritis Res Ther 2006; 8(2): R40.
71. van Gaalen F, Ioan-Facsinay A, Huizinga TW, Toes RE. The devil in the details: The emerging role of anti-citrulline autoimmunity in rheumatoid arthritis. J Immunol 2005; 175(9): 5575-80.
72. Klareskog L, Stolt P, Lundberg K et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54(1): 38-46.
73. van Gaalen FA, van Aken J, Huizinga TW et al.Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum2004; 50(7): 2113-21.
74. Hida S, Miura NN, Adachi Y, Ohno N. Influence of arginine deimination on antigenicity of fibrinogen. J Autoimmun 2004; 23(2): 141-50.
75. Hill JA, Southwood S, Sette A et al. Cutting edge: The conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003; 171(2): 538-41.
76. Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 1997; 7(4): 473-81.
77. Linn-Rasker SP, van der Helm, van Mil AH, van Gaalen FA et al. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis2006; 65(3): 366-71.
78. Dahlen E, Dawe K, Ohlsson L, Hedlund G. Dendritic cells and macrophages are the first and major producers of TNF-alpha in pancreatic islets in the nonobese diabetic mouse. J Immunol 1998; 160(7): 3585-93.
79. Ludewig B, Odermatt B, Landmann S, Hengartner H, Zinkernagel RM. Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue. J Exp Med 1998; 188(8): 1493-501.
80. Thompson AG, Thomas R. Induction of immune tolerance by dendritic cells: implications for preventative and therapeutic immunotherapy of autoimmune disease. Immunol Cell Biol 2002; 80(6): 509-19.
81. Harding B, Knight SC. The distribution of dendritic cells in the synovial fluids of patients with arthritis. Clin Exp Immunol 1986; 63(3): 594-600.
82. Thomas R, Lipsky PE. Presentation of self peptides by dendritic cells: possible implications for the pathogenesis of rheumatoid arthritis. Arthritis Rheum 199639(2): 183-90.
83. Pettit AR, MacDonald KPA, O'Sullivan B, Thomas R. Differentiated dendritic cells expressing nuclear RelB are predominantly located in rheumatoid synovial tissue perivascular mononuclear cell aggregates. Arthritis Rheum 2000; 43(4): 791-800.
84. Pettit AR, Ahern M, Zehntner S, Smith MD, Thomas R. Comparison of differentiated dendritic cell infiltration of autoimmune and osteoarthritic synovial tissue. Arthritis Rheum 2001; 44: 105-10.
85. Cavanagh LL, Boyce A, Smith L et al. Rheumatoid arthritis synovium contains plasmacytoid dendritic cells. Arthritis Res Ther 2005; 7(2): R230-40.
86. Van Krinks CH, Matyszak MK, Gaston JS. Characterization of plasmacytoid dendritic cells in inflammatory arthritis synovial fluid. Rheumatology (Oxford) 2004; 43(4): 453-60.
87. Camussi G, Lupia E. The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis. Drugs 1998; 55(5): 613-20.
88. Paleolog EM, Hunt M, Elliott MJ et al. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum 1996; 39(7): 1082-91.
89. Niimi M, Shirasugi N, Ikeda Y et al. Operational tolerance induced by pretreatment with donor dendritic cells under blockade of CD40 pathway. Transplantation 2001; 72(9): 1556-62.
90. Min WP, Gorczynski R, Huang XY, et al. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J Immunol 2000; 164(1): 161-7.
91. Romani N, Gruner S, Brang D et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180(1): 83-93.
92. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregu-lated by tumor necrosis factor alpha. J Exp Med 1994; 179(4): 1109-18.
93. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature1992; 360(6401): 258-61.
94. Fairchild PJ, Brook FA, Gardner RL et al. Directed differentiation of dendritic cells from mouse embryonic stem cells. Curr Biol 2000; 10(23): 1515-18.
95. Hirata S, Senju S, Matsuyoshi H et al. Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand. J Immunol 2005; 174(4): 1888-97.
96. Roncarolo MG, Levings MK, Traversari C. Differentiation of T regulatory cells by immature dendritic cells. J Exp Med 2001; 193(2): F5-9.
97. Hanks BA, Jiang J, Singh RA et al. Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat Med 2005; 11(2): 130-7.
98. Chang CC, Ciubotariu R, Manavalan JS et al.Tolerization of dendritic cells by T(S) cells: The crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 2002; 3(3): 237-43.
99. Colonna M, Nakajima H, Cella M. A family of inhibitory and activating Ig-like receptors that modulate function of lymphoid and myeloid cells. Semin Immunol 2000; 12(2): 121-7.
100. Colonna M, Navarro F, Bellon T et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 1997; 186(11): 1809-18.
101. Colonna M, Samaridis J, Cella M et al. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol 1998; 160(7): 3096-100.
102. Steinbrink K, Jonuleit H, Muller G et al. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 1999; 93(5): 1634-42.
103. Liu L, Rich BE, Inobe J, Chen W, Weiner HL. Induction of Th2 cell differentiation in the primary immune response: dendritic cells isolated from adherent cell culture treated with IL-10 prime naive CD4+ T cells to secrete IL-4. Int Immunol 1998; 10(8): 1017-26.
104. Steinbrink K, Graulich E, Kubsch S, Knop J, Enk AH. CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 2002; 99(7): 2468-76.
105. Viney JL, Mowat AM, O'Malley JM, Williamson E, Fanger NA. Expanding dendritic cells in vivo enhances the induction of oral tolerance. J Immunol1998; 160(12): 5815-25.
106. Vasu C, Dogan RN, Holterman MJ, Prabhakar BS. Selective induction of dendritic cells using granulocyte macrophage-colony stimulating factor, but not fms-like tyrosine kinase receptor 3-ligand, activates thy-roglobulin-specific CD4+/CD25+ T cells and suppresses experimental autoimmune thyroiditis. J Immunol 2003; 170(11): 5511-22.
107. Morikawa Y, Furotani M, Kuribayashi K, Matsuura N, Kakudo K. The role of antigen-presenting cells in the regulation of delayed-type hypersensitivity. I. Spleen dendritic cells. Immunology 1992; 77(1): 81-7.
108. Morikawa Y, Furotani M, Matsuura N, Kakudo K. The role of antigen-presenting cells in the regulation of delayed-type hypersensitivity. II. Epidermal Langerhans' cells and peritoneal exudate macrophages. Cell Immunol 1993; 152(1): 200-10.
109. Huang YM, Yang JS, Xu LY, Link H, Xiao BG. Autoantigen-pulsed dendritic cells induce tolerance to experimental allergic encephalomyelitis (EAE) in Lewis rats. Clin Exp Immunol 2000; 122(3): 437-44.
110. Xiao BG, Huang YM, Yang JS, Xu LY, Link H. Bone marrow-derived dendritic cells from experimental allergic encephalomyelitis induce immune tolerance to EAE in Lewis rats. Clin Exp Immunol 2001; 125(2): 300-9.
111. Yarilin D, Duan R, Huang YM, Xiao BG. Dendritic cells exposed in vitro to TGF-beta1 ameliorate experimental autoimmune myasthenia gravis. Clin Exp Immunol2002; 127(2): 214-19.
112. Jiang HR, Muckersie E, Robertson M, Forrester JV. Antigen-specific inhibition of experimental autoimmune uveoretinitis by bone marrow-derived immature dendritic cells. Invest Ophthalmol Vis Sci 2003; 44(4): 1598-607.
113. Okamoto S, Kosiewicz M, Caspi R, Streilein J. ACAID as a potential therapy for established experimental autoimmune uveitis. In: Nussenblatt RB, Whitcup SH, Cospi RR, Geri I, eds. Advances in Ocular Immunology. Proceedings of the 6th International Symposium on the Immunology and Immunopathology of the Eye, Bethesda, MD, 1994. Amsterdam: Elsevier, 1994: 195-8.
114. Vandenbark AA, Celnik B, Vainiene M, Miller SD, Offner H. Myelin antigen-coupled splenocytes suppress experimental autoimmune encephalomyelitis in Lewis rats through a partially reversible anergy mechanism. J Immunol 1995; 155(12): 5861-7.
115. Faunce DE, Terajewicz A, Stein-Streilein J. Cutting edge: in vitro-generated tolerogenic APC induce CD8+ T regulatory cells that can suppress ongoing experimental autoimmune encephalomyelitis. J Immunol2004; 172(4): 1991-5.
116. Khoury SJ, Gallon L, Verburg RR et al. Ex vivo treatment of antigen-presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat. J Immunol 1996; 157(8): 3700-5.
117. Menges M, Rossner S, Voigtlander C et al. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med 2002; 195(1): 15-21.
118. Thomas R. Signal 3 and its role in autoimmunity. Arthritis Res Ther 2004; 6: 26-7.
119. Xiao BG, Wu XC, Yang JS et al. Therapeutic potential of IFN-gamma-modified dendritic cells in acute and chronic experimental allergic encephalomyelitis. Int Immunol 2004; 16(1): 13-22.
120. Shinomiya M, Fazle Akbar SM, Shinomiya H, Onji M. Transfer of dendritic cells (DC) ex vivo stimulated with interferon-gamma (IFN-gamma) down-modu-lates autoimmune diabetes in non-obese diabetic (NOD) mice. Clin Exp Immunol 1999; 117(1): 38-43.
121. Clare-Salzler MJ, Brooks J, Chai A, Van Herle K, Anderson C. Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer. J Clin Invest 1992; 90(3): 741-8.
122. Papaccio G, Nicoletti F, Pisanti FA, Bendtzen K, Galdieri M. Prevention of spontaneous autoimmune diabetes in NOD mice by transferring in vitro antigen-pulsed syngeneic dendritic cells. Endocrinology 2000; 141(4): 1500-5.
123. Feili-Hariri M, Dong X, Alber SM et al.Immunotherapy of NOD mice with bone marrow-derived dendritic cells. Diabetes 1999; 48(12): 2300-8.
124. Ma L, Qian S, Liang X et al. Prevention of diabetes in NOD mice by administration of dendritic cells deficient in nuclear transcription factor-kappaB activity. Diabetes 2003; 52(8): 1976-85.
125. Charreire J. Immune mechanisms in autoimmune thyroiditis. Adv Immunol 1989; 46: 263-334.
126. Weetman AP, McGregor AM. Autoimmune thyroid disease: further developments in our understanding. Endocr Rev 1994; 15(6): 788-830.
127. Verginis P, Li HS, Carayanniotis G. Tolerogenic semimature dendritic cells suppress experimental autoimmune thyroiditis by activation of thyroglobu-lin-specific CD4+CD25+ T cells. J Immunol 2005; 174(11): 7433-9.
128. Liu Z, Xu X, Hsu HC et al. CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis. J Clin Invest 2003; 112(9): 1332-41.
129. Kim SH, Kim S, Oligino TJ, Robbins PD. Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL. Mol Ther. 2002; 6(5): 584-90.
130. Matsue H, Matsue K, Walters M et al. Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells. Nat Med1999; 5(8): 930-7.
131. Kim SH, Kim S, Evans CH et al. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol 2001; 166(5): 3499-505.
132. Morita Y, Yang J, Gupta R et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001; 107(10): 1275-84.
133. Chorny A, Gonzalez-Rey E, Fernandez-Martin A, Ganea D, Delgado M. Vasoactive intestinal peptide induces regulatory dendritic cells that can prevent acute graft-versus-host disease while maintain graft-versus-tumor. Blood 2006; 107: 3787-94.
134. Banchereau J, Palucka AK, Dhodapkar M et al.Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61(17): 6451-8.
135. Nestle FO, Banchereau J, Hart D. Dendritic cells: on the move from bench to bedside. Nat Med 2001; 7(7): 761-5.
136. Dhodapkar MV, Krasovsky J, Steinman RM, Bhardwaj N. Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. J Clin Invest 2000; 105(6): R9-R14.
137. Grouard G, Rissoan MC, Filgueira L et al. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med 1997; 185(6): 1101-11.
138. Rissoan MC, Soumelis V, Kadowaki N et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999; 283(5405): 1183-6.
139. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95(8): 2484-90.
140. Liu YJ, Blom B. Introduction: TH2-inducing DC2 for immunotherapy. Blood 2000; 95(8): 2482-3.
141. Huang YM, Hussien Y, Yarilin D et al. Interferon-beta induces the development of type 2 dendritic cells. Cytokine 2001; 13(5): 264-71.
142. Huang YM, Xiao BG, Ozenci V et al. Multiple sclerosis is associated with high levels of circulating dendritic cells secreting pro-inflammatory cytokines. J Neuroimmunol 1999; 99(1): 82-90.
143. Thompson AG, O'Sullivan BJ, Beamish H, Thomas R. T cells signaled by NF-kappa B- dendritic cells are sensitized not anergic to subsequent activation. J Immunol 2004; 173(3): 1671-80.
144. Morse MA, Deng Y, Coleman D et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999; 5(6): 1331-8.
145. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001; 294(5546): 1540-3.
146. Amoura Z, Piette JC, Chabre H et al. Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus: correlation with serum antinucleo-some antibody titers and absence of clear association with disease activity. Arthritis Rheum 1997; 40(12): 2217-25.
147. Vallin H, Blomberg S, Alm GV, Cederblad B, Ronnblom L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol1999; 115(1): 196-202.
148. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001; 159(1): 237-43.
149. Kelly KM, Zhuang H, Nacionales DC et al. Endogenous adjuvant' activity of the RNA components of lupus autoantigens Sm/RNP and Ro 60. Arthritis Rheum 2006; 54(5): 1557-67.
150. Savarese E, Chae OW, Trowitzsch S et al. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 2006; 107(8): 3229-34.
151. Vollmer J, Tluk S, Schmitz C et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 2005; 202(11): 1575-85.
152. Page G, Lebecque S, Miossec P. Anatomic localization of immature and mature dendritic cells in an ectopic lymphoid organ: correlation with selective chemokine expression in rheumatoid synovium. J Immunol 2002; 168: 5333-41.
153. Fan L, Reilly CR, Luo Y, Dorf ME, Lo D. Cutting edge: ectopic expression of the chemokine TCA4/SLC is sufficient to trigger lymphoid neogenesis. J Immunol2000; 164(8): 3955-9.
154. Shi K, Hayashida K, Kaneko M et al. Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunol 2001; 166(1): 650-5.
155. Martin E, Capini C, Duggan E, et al. Antigen-specific suppression of established arthritis by dendritic cells deficient in NF-kappa B. Arthritis Rhem 2007; 56: 2255-2266.